Mangalam Drugs & Organics Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Mangalam Drugs & Organics.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth	18.7%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

No updates

Recent updates

Little Excitement Around Mangalam Drugs & Organics Limited's (NSE:MANGALAM) Revenues As Shares Take 25% Pounding

Mar 28

Mangalam Drugs & Organics Limited's (NSE:MANGALAM) Shares Lagging The Industry But So Is The Business

Feb 07

Estimating The Fair Value Of Mangalam Drugs & Organics Limited (NSE:MANGALAM)

Oct 20

Is Mangalam Drugs & Organics (NSE:MANGALAM) A Risky Investment?

Mar 29

These 4 Measures Indicate That Mangalam Drugs & Organics (NSE:MANGALAM) Is Using Debt Extensively

May 31

A Look At The Fair Value Of Mangalam Drugs & Organics Limited (NSE:MANGALAM)

Apr 06

We Think Mangalam Drugs & Organics (NSE:MANGALAM) Is Taking Some Risk With Its Debt

Jan 03

Here's Why Mangalam Drugs & Organics (NSE:MANGALAM) Can Manage Its Debt Responsibly

May 23

Is Mangalam Drugs & Organics (NSE:MANGALAM) A Risky Investment?

Jan 04

Do Its Financials Have Any Role To Play In Driving Mangalam Drugs & Organics Limited's (NSE:MANGALAM) Stock Up Recently?

Nov 12

A Look At The Intrinsic Value Of Mangalam Drugs & Organics Limited (NSE:MANGALAM)

Sep 20

Does Mangalam Drugs & Organics's (NSE:MANGALAM) Statutory Profit Adequately Reflect Its Underlying Profit?

Aug 05

We Think Mangalam Drugs & Organics (NSE:MANGALAM) Can Stay On Top Of Its Debt

Jul 01

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Mangalam Drugs & Organics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NSEI:MANGALAM - Analysts future estimates and past financials data (INR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2023	3,595	-170	N/A	N/A	N/A
9/30/2023	3,245	-171	N/A	N/A	N/A
6/30/2023	3,477	-113	N/A	N/A	N/A
3/31/2023	3,702	13	116	395	N/A
12/31/2022	4,109	123	N/A	N/A	N/A
9/30/2022	4,426	159	44	279	N/A
6/30/2022	4,505	182	N/A	N/A	N/A
3/31/2022	4,509	197	-20	257	N/A
12/31/2021	4,185	151	N/A	N/A	N/A
9/30/2021	4,058	175	-73	315	N/A
6/30/2021	3,813	241	N/A	N/A	N/A
3/31/2021	3,800	280	-39	275	N/A
12/31/2020	3,774	309	N/A	N/A	N/A
9/30/2020	3,507	261	221	361	N/A
6/30/2020	3,210	158	N/A	N/A	N/A
3/31/2020	2,824	83	236	305	N/A
12/31/2019	2,423	-28	N/A	N/A	N/A
9/30/2019	2,290	-89	N/A	N/A	N/A
6/30/2019	2,336	-80	N/A	N/A	N/A
3/31/2019	2,276	-80	124	217	N/A
12/31/2018	2,467	10	N/A	N/A	N/A
9/30/2018	2,720	114	N/A	N/A	N/A
6/30/2018	2,833	164	N/A	N/A	N/A
3/31/2018	2,794	199	86	246	N/A
12/31/2017	2,904	247	N/A	N/A	N/A
9/30/2017	2,983	248	N/A	N/A	N/A
6/30/2017	3,044	233	N/A	N/A	N/A
3/31/2017	3,029	223	N/A	428	N/A
12/31/2016	2,906	227	N/A	N/A	N/A
9/30/2016	2,943	203	N/A	N/A	N/A
6/30/2016	2,919	181	N/A	N/A	N/A
3/31/2016	2,952	160	N/A	218	N/A
12/31/2015	3,001	140	N/A	N/A	N/A
9/30/2015	2,807	110	N/A	N/A	N/A
6/30/2015	2,516	101	N/A	N/A	N/A
3/31/2015	2,207	61	N/A	140	N/A
12/31/2014	1,783	65	N/A	N/A	N/A
9/30/2014	1,556	56	N/A	N/A	N/A
6/30/2014	1,425	26	N/A	N/A	N/A
3/31/2014	1,227	-30	N/A	75	N/A
12/31/2013	1,320	-60	N/A	N/A	N/A
9/30/2013	1,293	-84	N/A	N/A	N/A
6/30/2013	1,195	-116	N/A	N/A	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if MANGALAM's forecast earnings growth is above the savings rate (6.7%).

Earnings vs Market: Insufficient data to determine if MANGALAM's earnings are forecast to grow faster than the Indian market

High Growth Earnings: Insufficient data to determine if MANGALAM's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if MANGALAM's revenue is forecast to grow faster than the Indian market.

High Growth Revenue: Insufficient data to determine if MANGALAM's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if MANGALAM's Return on Equity is forecast to be high in 3 years time

Mangalam Drugs & Organics Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Little Excitement Around Mangalam Drugs & Organics Limited's (NSE:MANGALAM) Revenues As Shares Take 25% Pounding

Now 22% undervalued

Third quarter 2024 earnings released: EPS: ₹0.31 (vs ₹0.27 in 3Q 2023)

Now 24% undervalued

Mangalam Drugs & Organics Limited's (NSE:MANGALAM) Shares Lagging The Industry But So Is The Business

Second quarter 2024 earnings released: ₹2.26 loss per share (vs ₹1.41 profit in 2Q 2023)

Now 24% undervalued after recent price drop

Estimating The Fair Value Of Mangalam Drugs & Organics Limited (NSE:MANGALAM)

Mangalam Drugs & Organics Limited to Report Q2, 2024 Results on Nov 14, 2023

Now 20% undervalued after recent price drop

First quarter 2024 earnings released: ₹6.02 loss per share (vs ₹1.92 profit in 1Q 2023)

Mangalam Drugs & Organics Limited to Report Q1, 2024 Results on Aug 10, 2023

Full year 2023 earnings released: EPS: ₹0.80 (vs ₹12.42 in FY 2022)

Mangalam Drugs & Organics Limited to Report Q4, 2023 Results on May 30, 2023

Is Mangalam Drugs & Organics (NSE:MANGALAM) A Risky Investment?

Third quarter 2023 earnings released: EPS: ₹0.27 (vs ₹2.54 in 3Q 2022)

Mangalam Drugs & Organics Limited to Report Q3, 2023 Results on Feb 13, 2023

Second quarter 2023 earnings released: EPS: ₹1.41 (vs ₹2.86 in 2Q 2022)

Second quarter 2023 earnings released: EPS: ₹1.41 (vs ₹2.86 in 2Q 2022)

Mangalam Drugs & Organics Limited to Report Q2, 2023 Results on Nov 11, 2022

Mangalam Drugs & Organics Limited, Annual General Meeting, Sep 28, 2022

First quarter 2023 earnings released: EPS: ₹1.92 (vs ₹2.79 in 1Q 2022)

Mangalam Drugs & Organics Limited to Report Q1, 2023 Results on Aug 05, 2022

Chairman & MD recently sold ₹1.3m worth of stock

Investor sentiment improved over the past week

These 4 Measures Indicate That Mangalam Drugs & Organics (NSE:MANGALAM) Is Using Debt Extensively

Full year 2022 earnings released: EPS: ₹12.42 (vs ₹17.67 in FY 2021)

Mangalam Drugs & Organics Limited to Report Q4, 2022 Final Results on May 26, 2022

Investor sentiment improved over the past week

A Look At The Fair Value Of Mangalam Drugs & Organics Limited (NSE:MANGALAM)

Mangalam Drugs & Organics Limited Announces Executive Changes

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

We Think Mangalam Drugs & Organics (NSE:MANGALAM) Is Taking Some Risk With Its Debt

Investor sentiment improved over the past week

Insufficient new directors

Insufficient new directors

First quarter 2022 earnings released: EPS ₹2.79 (vs ₹6.13 in 1Q 2021)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Here's Why Mangalam Drugs & Organics (NSE:MANGALAM) Can Manage Its Debt Responsibly

Full year 2021 earnings released: EPS ₹17.67 (vs ₹5.21 in FY 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

New 90-day low: ₹112

Third quarter 2021 earnings released: EPS ₹4.07 (vs ₹1.04 in 3Q 2020)

Mangalam Drugs & Organics Limited to Report Q3, 2021 Results on Feb 11, 2021

New 90-day low: ₹127

Is Mangalam Drugs & Organics (NSE:MANGALAM) A Risky Investment?

Mangalam Drugs & Organics Limited Announces Resignation of Prashant J. Pandit as Independent Director

New 90-day low: ₹129

Mangalam Drugs & Organics Limited Announces Change in Directorate

New 90-day high: ₹169

Second quarter 2021 earnings released: EPS ₹7.00

Do Its Financials Have Any Role To Play In Driving Mangalam Drugs & Organics Limited's (NSE:MANGALAM) Stock Up Recently?

A Look At The Intrinsic Value Of Mangalam Drugs & Organics Limited (NSE:MANGALAM)

New 90-day high - ₹90.80

Does Mangalam Drugs & Organics's (NSE:MANGALAM) Statutory Profit Adequately Reflect Its Underlying Profit?

Mangalam Drugs & Organics Limited to Report Q1, 2021 Results on Aug 10, 2020

We Think Mangalam Drugs & Organics (NSE:MANGALAM) Can Stay On Top Of Its Debt

Mangalam Drugs & Organics Limited to Report Q4, 2020 Results on Jun 29, 2020

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies